ID Source | ID |
---|---|
PubMed CID | 6450536 |
SCHEMBL ID | 1649845 |
MeSH ID | M0185662 |
Synonym |
---|
silipide |
idb-106 |
4h-1-benzopyran-4-one, 2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-, (2r-(2alpha,3beta,6(2r*,3r*)))-, mixt. with soya phosphatidylcholines |
idb 1016 |
134499-06-2 |
SCHEMBL1649845 |
[1-[(4e,9e,12e)-hexadeca-4,9,12-trienoyl]oxy-3-[(6e,10e,12e)-hexadeca-6,10,12-trienoyl]oxypropan-2-yl] 2-(trimethylazaniumyl)ethyl phosphate;(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3- |
IdB 1016 is a new silybin-phospholipid complex which is more bioavailable than the flavonoid sily bin itself. It displays free radical scavenging and antioxidant properties in liver microsomes.
Excerpt | Reference | Relevance |
---|---|---|
"IdB 1016 is a new silybin-phospholipid complex which is more bioavailable than the flavonoid silybin itself and displays free radical scavenging and antioxidant properties in liver microsomes. " | ( Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Albano, E; Carini, R; Comoglio, A; Poli, G, 1992) | 1.93 |
"IdB 1016 is a complex of silybin (the main active component of silymarin) and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin. " | ( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G, ) | 1.87 |
Excerpt | Reference | Relevance |
---|---|---|
"Treatment with IdB 1016 is associated with reduced body iron stores, especially among patients with advanced fibrosis stage." | ( Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. Bares, JM; Berger, J; Kowdley, KV; Messner, DJ; Nelson, JE; Schildt, S; Standish, LJ, 2008) | 0.7 |
Excerpt | Reference | Relevance |
---|---|---|
" In order to assess its pharmacokinetic profile in man, plasma silybin levels were determined after administration of single oral doses of IdB 1016 and silymarin (equivalent to 360 mg silybin) to 9 healthy volunteers." | ( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G, ) | 0.63 |
"To develop a new HPLC-UV method of determining silybin in human plasma and to study the pharmacokinetic of silybin-phosphatidylcholine complex (silybinin capsules) in healthy male Chinese volunteers using the new developed method." | ( Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. Gao, J; Li, W; Liu, CX; Zhao, HZ, ) | 0.13 |
IdB 1016 is a complex of silybin and phosphatidylcholine. In animal models shows greater oral bioavailability and therefore greater pharmacological activity.
Excerpt | Reference | Relevance |
---|---|---|
" These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin." | ( Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Gatti, G; Perucca, E; Schandalik, R, 1992) | 0.28 |
" Our results indicate a superior bioavailability of silybin administered orally as IdB 1016." | ( Comparative bioavailability of Silipide, a new flavanolignan complex, in rats. Giachetti, C; Magistretti, MJ; Morazzoni, P; Zanolo, G, ) | 0.36 |
"IdB 1016 is a complex of silybin (the main active component of silymarin) and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin." | ( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G, ) | 1.87 |
" However, such an effect is lost when pure silybin in amounts comparable to those present in Silipide is administered instead, due to the low bioavailability of uncomplexed flavonoid." | ( Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Albano, E; Comoglio, A; Malandrino, S; Poli, G; Tomasi, A, 1995) | 0.29 |
" The relative bioavailability of silipide (calculated in the target organ as the ratio between AUCs of cumulative biliary excretion curves) was 10-fold higher than that of silymarin." | ( Comparative pharmacokinetics of silipide and silymarin in rats. Malandrino, S; Montalbetti, A; Morazzoni, P; Pifferi, G, ) | 0.13 |
" We also aimed to establish the plasma and tumour bioavailability of silybin after repeated administration of IdB 1016." | ( Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Apollonio, P; Bombardelli, E; Ferlini, C; Gallo, D; Giacomelli, S; Morazzoni, P; Prislei, S; Raspaglio, G; Riva, A; Scambia, G, 2003) | 0.77 |
"The aim of the present study was to evaluate the hepatoprotective and the antifibrotic properties of a new silybin-phosphatidylcholine-Vitamin E complex, characterised by elevated oral bioavailability and lipophilicity, on rat hepatic fibrosis induced by dimethylnitrosamine administration and by bile duct ligation." | ( Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Bendia, E; Benedetti, A; Candelaresi, C; De Minicis, S; Di Sario, A; Marzioni, M; Omenetti, A; Taffetani, S, 2005) | 0.33 |
" The potential for enhanced bioavailability of a phytosome complex containing phosphatidylcholine and silybin, the primary active flavonolignan in silymarin extract, was tested in dogs." | ( Bioavailability of a silybin-phosphatidylcholine complex in dogs. Filburn, CR; Griffin, DW; Kettenacker, R, 2007) | 0.34 |
Excerpt | Relevance | Reference |
---|---|---|
"4 hours after dosing and declined thereafter with a half-life of about 2 hours." | ( Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Gatti, G; Perucca, E, 1994) | 0.29 |
" A group of eight beagles (four males, four females) were dosed orally with a silybin-phosphatidylcholine complex (SPC) and a commercially available standardized silymarin extract containing equivalent levels of silybin." | ( Bioavailability of a silybin-phosphatidylcholine complex in dogs. Filburn, CR; Griffin, DW; Kettenacker, R, 2007) | 0.34 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (47.37) | 18.2507 |
2000's | 9 (47.37) | 29.6817 |
2010's | 1 (5.26) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.82) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 6 (25.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (75.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |